IIFL Capital Q2 FY27 Earnings Call — Analysis (NSE: IIFLCAPS)
IIFL Capital posted 22% YoY operational revenue growth to ₹722 Cr and ₹206 Cr operational PBT, while securing regulatory approvals for Fairfax's 51% stake acquisition and announcing MD succession.
Result quality: stable — Steady quarter. Management sentiment: optimistic.
The take
Q2FY27 Consolidated Operational Revenue ₹722 Cr ( +22% YoY ) .
Results
Operational revenue grew 22% YoY to ₹722 Cr with operational PBT before MTM up 25% YoY to ₹206 Cr, offset by ₹32 Cr MTM loss on BSE shares.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Consolidated Operational Revenue | ₹722 Cr | +22% | yoy · Q2FY27 |
| Consolidated Operational Revenue | ₹722 Cr | +14% | qoq · Q2FY27 |
| Operational PBT (before MTM) | ₹206 Cr | +25% | yoy · Q2FY27 |
| Operational PBT (before MTM) | ₹206 Cr | +40% | qoq · Q2FY27 |
| Retail Equities Revenue | ₹316 Cr | +17% | yoy · Q2FY27 |
| Institutional and Banking Revenue | ₹245 Cr | +18% | qoq · Q2FY27 |
| Financial Products Distribution (FPD) Income | ₹159 Cr | +23% | yoy · Q2FY27 |
| MTM Loss on BSE Shares | ₹32 Cr | none · Q2FY27 · Adverse BSE share price movement | |
| Average Daily Turnover (ADTO) | ₹305073 Cr | +16% | yoy · Q2FY27 |
| Finance Costs | ₹75 Cr | +40% | yoy · Q2FY27 · Increased borrowings |
| Employee Costs | ₹194 Cr | +26% | yoy · Q2FY27 · Headcount increase, variable pay, and wage inflation |
Guidance
Fairfax 51% acquisition via preferential allotment and open offer is expected to close in November 2026, with quarterly employee expenses guided around ₹192-194 Cr.
Key themes
Fairfax acquisition, succession, and business scaling
Operational commentary
- Fairfax Mauritius Investments has received all regulatory and shareholder approvals for acquiring a 51% controlling stake via preferential allotment and open offer.
- Proposed incorporation of a wholly-owned NBFC subsidiary to offer lending and credit solutions to HNI clients, subject to RBI approval.
- Leadership succession announced: Vasudev Jagannath appointed Additional & Whole-Time Director, taking over as Managing Director effective January 1, 2027; R. Venkataraman to remain on Board.
- In-house asset manufacturing AUM stands at roughly ₹4,500 Cr across AMC/AIF/PMS products.
- Company continues to hold ~5.95 lakh shares of BSE as a legacy investment.
Analyst Q&A
Q. Breakup between institutional broking and investment banking revenue in Q2?
Institutional broking was approximately ₹250 Cr and institutional investment banking was roughly ₹200 Cr out of the combined institutional revenue.
Q. How will Fairfax capital infusion funds be utilized?
Bulk of the funds will be deployed into margin funding book expansion and repayment of borrowings.
Q. What was the exact loss from the wealth management/FPD business for H1?
Acknowledged the wealth business is making a loss but did not have the exact number on hand and promised to share it offline.
Q. Will promoters tender shares in the open offer?
Clarified that promoters will not tender in the open offer, and will only sell shares to Fairfax if the open offer does not reach the 51% threshold.
Q. Long-term strategy on insurance distribution vs capital market distribution?
Focus is shifting to capital markets distribution over insurance distribution, and management is open to exploring strategic options/sale of the insurance distribution business.
Research and educational content only. Not investment advice.